Overview

Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma

Status:
Withdrawn

Trial end date:
2014-01-01

Target enrollment:

Participant gender:

Summary

A phase 2, open-label randomized, multicenter trial to compare CC-486 in combination with Abraxane administered weekly with respect to overall survival, objective tumor response rate and Progression-Free Survival (PFS) in participants diagnosed with metastatic malignant melanoma.

Phase:

Phase 2

Details

Lead Sponsor:

Celgene Corporation

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel